Search

Your search keyword '"Montuori, Claudio"' showing total 8 results
Start Over Author "Montuori, Claudio" Publisher mdpi ag
8 results on '"Montuori, Claudio"'

1. Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab

Author

Ottaviano, Giancarlo, primary, De Corso, Eugenio, additional, Cantone, Elena, additional, Ciofalo, Andrea, additional, Saccardo, Tommaso, additional, Bernardi, Riccardo, additional, Mairani, Edoardo, additional, Montuori, Claudio, additional, Roccuzzo, Giuseppe, additional, Soldati, Livia, additional, Randon, Benedetto, additional, Zampollo, Sonny, additional, Chicco, Alessandra Di, additional, Visconti, Francesca, additional, Scarpa, Bruno, additional, and Nicolai, Piero, additional

Published
2023
Full Text
View/download PDF

3. Proposal for a Structured Outpatient Clinic for Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps in the First Year of Treatment

Author

Torretta, Sara, primary, De Corso, Eugenio, additional, Nava, Nicolò, additional, Fraccaroli, Francesca, additional, Ferrucci, Silvia Mariel, additional, Settimi, Stefano, additional, Montuori, Claudio, additional, Porru, Davide Paolo, additional, Spanu, Camilla, additional, D’Agostino, Giuseppe, additional, Marzano, Angelo Valerio, additional, and Pignataro, Lorenzo, additional

Published
2022
Full Text
View/download PDF

4. Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study

Author

Gallo, Stefania, primary, Castelnuovo, Paolo, additional, Spirito, Luca, additional, Feduzi, Marta, additional, Seccia, Veronica, additional, Visca, Dina, additional, Spanevello, Antonio, additional, Statuti, Erica, additional, Latorre, Manuela, additional, Montuori, Claudio, additional, Rizzi, Angela, additional, Boccabella, Cristina, additional, Bonini, Matteo, additional, and De Corso, Eugenio, additional

Published
2022
Full Text
View/download PDF

5. Sinonasal Biomarkers Defining Type 2-High and Type 2-Low Inflammation in Chronic Rhinosinusitis with Nasal Polyps

Author

De Corso, Eugenio, primary, Baroni, Silvia, additional, Settimi, Stefano, additional, Onori, Maria Elisabetta, additional, Mastrapasqua, Rodolfo Francesco, additional, Troiani, Eliana, additional, Moretti, Giacomo, additional, Lucchetti, Donatella, additional, Corbò, Marco, additional, Montuori, Claudio, additional, Cantiani, Alessandro, additional, Porru, Davide Paolo, additional, Lo Verde, Simone, additional, Di Bella, Giuseppe Alberto, additional, Caruso, Cristiano, additional, and Galli, Jacopo, additional

Published
2022
Full Text
View/download PDF

6. Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A “Real-Life” Observational Study in the First Year of Treatment

Author

De Corso, Eugenio, primary, Settimi, Stefano, additional, Montuori, Claudio, additional, Corbò, Marco, additional, Passali, Giulio Cesare, additional, Porru, Davide Paolo, additional, Lo Verde, Simone, additional, Spanu, Camilla, additional, Penazzi, Daniele, additional, Di Bella, Giuseppe Alberto, additional, Nucera, Eleonora, additional, Bonini, Matteo, additional, Paludetti, Gaetano, additional, and Galli, Jacopo, additional

Published
2022
Full Text
View/download PDF

8. Dupilumab Improves Facial Pain and Reduces Rescue Treatments in Patients with CRSwNP and Recalcitrant Frontal Sinusitis.

Author

De Corso E, Settimi S, Penazzi D, D'Agostino G, Corbò M, Rigante M, Montuori C, Rizzuti A, Pacilli MC, Di Cesare T, Lo Verde S, Rizzi A, Chini R, and Galli J

Abstract

Recalcitrant frontal sinusitis in patients with chronic rhinosinusitis and nasal polyps (CRSwNP) has a negative impact on their quality of life due to frontal pain and a high risk of sinus occlusion, thus necessitating antibiotics, systemic corticosteroids, and multiple surgeries. The aim of this study was to assess the efficacy of dupilumab in reducing frontal pain and the need for rescue treatments for recalcitrant frontal sinusitis in patients with CRSwNP. We enrolled a cohort of 10 patients with severe uncontrolled CRSwNP and concomitant recurrent frontal sinusitis associated with severe facial pain measured by MIDAS score who were treated with dupilumab 300 mg every 2 weeks and followed for at least 12 months. The mean MIDAS score decreased from 45.6 ± 10.7 at baseline to 1.3 ± 2.3 at 6 months ( p < 0.05). VAS craniofacial pain decreased from 7.3 ± 1.6 at baseline to 1.2 ± 1.5 at 6 months ( p < 0.05). No patient needed oral corticosteroids during treatment with dupilumab ( p < 0.05), and the use of analgesics decreased from 9.6 ± 3.1 NSAID pills/week in the last 2 months at baseline to 0.6 ± 1.3 at 1 year of follow-up ( p < 0.05). Our results demonstrated that use of subcutaneous dupilumab can improve symptom control, including recurrent severe cranio-facial pain, and reduce the need for rescue medical treatments (systemic steroids and NSAID) in patients with severe uncontrolled CRSwNP and concomitant recurrent frontal sinusitis.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results